Amicus Therapeutics Inc (FOLD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Pompe Disease Therapy Revenue: $21 million in Q3 2024, a 33% increase from Q2 2024. Cost of Goods Sold: 9.4% of net sales in Q3 2024. GAAP Operating Expenses: $107 million in Q3 2024, a decrease of 4% from Q3 2023. Non-GAAP Operating Expenses: $83 million in Q3 2024, an 8% decrease from Q3 2023. Net Loss (GAAP): $7 million or 2 per share in Q3 2024. Non-GAAP Net Income: $31 million or a profit of 10 per share in Q3 2024. Cash and Marketable Securities: $250 million as of September 30, 2024. Full Year Revenue Growth Guidance: Increased to 30-32% for 2024. Galafold Full Year Revenue Growth Guidance: Increased to 16-18% for 2024. Pompe Disease Therapy Full Year Sales Guidance: Raised to $69-71 million for 2024. Non-GAAP Operating Expense Guidance: Lowered to $340-350 million for 2024. Warning! GuruFocus has detected 3 Warning Signs with FOLD. Release Date: November 06, 2024 For the complete transcript of the earnings call, please refer to the full earnings call
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Amicus Therapeutics, Inc. (NASDAQ: FOLD) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $12.00 price target on the stock, down previously from $17.00.MarketBeat
FOLD
Earnings
- 11/6/24 - Beat
FOLD
Sec Filings
- 12/3/24 - Form 4
- 12/2/24 - Form 144
- 11/14/24 - Form SC
- FOLD's page on the SEC website